BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9534706)

  • 1. Recurrent follicular carcinoma-oxyphilic cell type (Hürthle cell carcinoma) of the thyroid, imaging with iodine-131 and technetium-99m tetrofosmin before and after radiotherapy.
    Bomanji JB; Gacinovic S; Gaze MN; Costa DC; Ell PJ
    Br J Radiol; 1998 Jan; 71(841):87-9. PubMed ID: 9534706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
    Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
    J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
    Lind P; Gallowitsch HJ
    Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive thyroid cancer scintigraphy using 99Tcm-tetrofosmin (Myoview): a preliminary report.
    Nĕmec J; Nývltová O; Preiningerová M; Vlcek P; Racek P; Novák Z; Blazek T; Zimák J
    Nucl Med Commun; 1995 Aug; 16(8):694-7. PubMed ID: 7491183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technetium-99m-sestamibi uptake by recurrent Hurthle cell carcinoma of the thyroid.
    Balon HR; Fink-BennetT D; Stoffer SS
    J Nucl Med; 1992 Jul; 33(7):1393-5. PubMed ID: 1535374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma.
    Lind P; Gallowitsch HJ; Langsteger W; Kresnik E; Mikosch P; Gomez I
    J Nucl Med; 1997 Mar; 38(3):348-52. PubMed ID: 9074515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 99Tcm-tetrofosmin with 201Tl and 131I in the detection of differentiated thyroid cancer metastases.
    Nishiyama Y; Yamamoto Y; Ono Y; Takahashi K; Nakano S; Satoh K; Ohkawa M; Tanabe M
    Nucl Med Commun; 2000 Oct; 21(10):917-23. PubMed ID: 11130332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thallium-201, technetium-99m-tetrofosmin and iodine-131 in detecting differentiated thyroid carcinoma metastases.
    Unal S; Menda Y; Adalet I; Boztepe H; Ozbey N; Alagöl F; Cantez S
    J Nucl Med; 1998 Nov; 39(11):1897-902. PubMed ID: 9829579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Technetium-99m tetrofosmin uptake in insular thyroid carcinoma. A comparison with iodine-131.
    Degirmenci B; Aydin A; Comlekci A; Ozdogan O; Bekis R
    Clin Nucl Med; 2003 May; 28(5):385-8. PubMed ID: 12702934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tc-99m-tetrofosmin scintigraphy: an alternative scintigraphic method for following up differentiated thyroid carcinoma--preliminary results.
    Gallowitsch HJ; Kresnik E; Mikosch P; Pipam W; Gomez I; Lind P
    Nuklearmedizin; 1996 Dec; 35(6):230-5. PubMed ID: 8976503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of medullary thyroid carcinoma metastases by 201Tl, 99Tcm(V)DMSA, 99Tcm-MIBI and 99Tcm-tetrofosmin.
    Adalet I; Koçak M; Ogŭz H; Alagöl F; Cantez S
    Nucl Med Commun; 1999 Apr; 20(4):353-9. PubMed ID: 10319355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technetium-99m tetrofosmin and technetium-99m sestamibi imaging of multiple metastases from differentiated thyroid carcinoma.
    Kosuda S; Yokoyama H; Katayama M; Yokokawa T; Kusano S; Yamamoto O
    Eur J Nucl Med; 1995 Oct; 22(10):1218-20. PubMed ID: 8542909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of thyroid nodules with technetium-99m tetrofosmin dual-phase scintigraphy.
    Kresnik E; Gallowitsch HJ; Mikosch P; Molnar M; Pipam W; Gomez I; Lind P
    Eur J Nucl Med; 1997 Jul; 24(7):716-21. PubMed ID: 9211755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.
    Feine U; Lietzenmayer R; Hanke JP; Held J; Wöhrle H; Müller-Schauenburg W
    J Nucl Med; 1996 Sep; 37(9):1468-72. PubMed ID: 8790195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear imaging in the management of thyroid carcinoma.
    Cavalieri RR
    Thyroid; 1996 Oct; 6(5):485-92. PubMed ID: 8936676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scintigraphy with [111In]octreotide and 201Tl in a Hürthle cell thyroid carcinoma without detectable radio-iodine uptake. Report of a case and review of the literature.
    Kostoglou-Athanassiou I; Pappas A; Gogou L; Kaldrymides P
    Horm Res; 2003; 60(4):205-8. PubMed ID: 14530610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. F-18 FDG uptake by recurrent Hürthle cell carcinoma of the thyroid using high-energy planar scintigraphy.
    Blount CL; Dworkin HJ
    Clin Nucl Med; 1996 Nov; 21(11):831-3. PubMed ID: 8922841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Technetium-99m-tetrofosmin imaging of differentiated mixed thyroid cancer.
    Klain M; Maurea S; Lastoria S; Cuocolo A; Colao A; Lombardi G; Salvatore M
    J Nucl Med; 1995 Dec; 36(12):2248-51. PubMed ID: 8523115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of 99Tcm-tetrofosmin in the evaluation of thyroid nodules.
    Kanmaz B; Erdil TY; Yardi OF; Sayman HB; Kabasakal L; Sönmezoglu K; Onsel C; Düren M; Nisli C; Ozcan K; Uslu I
    Nucl Med Commun; 2000 Apr; 21(4):333-9. PubMed ID: 10845221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of follicular and Hürthle cell neoplasms of the thyroid gland.
    McHenry CR; Sandoval BA
    Surg Oncol Clin N Am; 1998 Oct; 7(4):893-910. PubMed ID: 9735140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.